The Texas A&M Interprofessional Pharmacogenomics PILOT Whole Genome Sequencing Cohort for Polypharmacy Patients and Adverse Drug Reactions

What this Trial Is About

Researchers are evaluating adverse drug reactions (ADRs) related to taking multiple medications (polypharmacy) in patients at risk, using advanced pharmacogenomic technology. The study aims to improve medication management by integrating genomic data into electronic decision support tools. It also seeks to assess the activity of liver enzymes involved in drug metabolism and test the feasibility of combining whole genome sequencing data with electronic medical records and clinical workflows. Participants will be observed using pharmacogenomic tests, including genotyping and research-use-only whole genome sequencing, alongside comprehensive clinical assessments. The study will develop and refine a clinical decision support dashboard to help identify medication regimens that may need adjustment, replacement, or discontinuation. The research involves collecting genetic, urine, and blood samples and linking this information with patient medical histories and medication use patterns. During the study, participants will provide samples and undergo history and physical examinations. Researchers will track adverse drug reactions and emergency department visits over 180 days. The study will monitor pharmacogenomic genotypes paired with ADRs, using data to improve personalized medication guidance. Participants' safety and medication responses will be closely followed, with results aimed at supporting better care decisions in polypharmacy management.

IPGx PILOT Whole Genome Sequencing Extension Cohort